Advertisement
Advertisement

TheBody.com/TheBodyPRO.com cover the XIX International AIDS Conference (AIDS 2012)

First Report: Atazanavir-Related Gallstones (Cholelithiasis)

July/August 2012

A poster presentation included the first report of atazanavir-related gallstones.

Following two cases of gallstones in patients on atazanavir reported to the pharmacovigilence departments of two hospitals in western France, Poinsignon and colleagues performed a case review for all patients attending these clinics between 2008 and 2011. The review was limited to cases where spectrophotometry analysis of the stones showed significant levels of atazanavir.

They identified 11 patients (10 men, 1 woman) who had underdone cholecystectomy. Mean age was 49 years (range 32-82) and mean BMI of 23 kg/m2 and all were virally suppressed on atazanavir-based combinations (mean atazanavir duration of 50 months). The mean CD4 cell count was 683 (± 310) cells/mm3.

Advertisement
Co-morbidities included HCV-coinfection (n=6, of whom 1 had cirrhosis, 1 hepatocellular carcinoma, and 1 HBV and HDV co-infections), past intravenous drug use (n=3), haemophilia A (n=2), and chronic alcohol abuse (n=2). Final diagnoses included acute pancreatitis (n=3), acute cholecystitis (n=3), and angiocholitis (n=1). Ten patients underwent laperoscopic cholecystectomy, and one had endoscopic sphincterotomy (two patients had both).

Atazanavir was found in biliary stones from eight patients, composing 10% to 100% of the total weight (mean 72%), but included 4 patients with 100% composition. Three other patients did not contain atazanavir but included bilirubinate calcium, carbapatite and cholesterol. Atazanavir was boosted in 6/8 (using doses of 150 mg to 400 mg) and unboosted in 2/8. Atazanavir plasma levels for all patients were within the therapeutic range.

Biochemical and infrared spectrometry analysis of the stones led the researchers to determine this was related to direct atazanavir precipitation n 8/11 cases and to biliary elimination through the UGT1A1 metabolic pathway in 3/11 cases.

All patients switched atazanavir to raltegravir, an NNRTI or an alternative PI. All patients survived and none relapsed, with a mean follow-up of three years.

The authors noted that these cases were mostly in men coinfected with HCV with mean atazanavir exposure of four years and that based on these cases they estimated an incidence in their region of 2-2.5 cases per 1000 patients years (of atazanavir).

They also concluded, "atazanavir-treated patients with abdominal pain necessitate liver function and lipase tests as well as hepatobiliary ultrasound examination to evaluate medico-surgical care" and that possible calculus analysis must be undertaken and the case reported to drug safety surveillance systems.


Reference

Poinsignon Y et al. Complicated atazanavir-associated cholelithiasis: a report of eight documented cases among 11 cases. 19th International AIDS Conference. 22-27 July 2012, Washington. Poster abstract MOPE099.

Links to other websites are current at date of posting but not maintained.




Visit HIV i-Base's website to find out more about their activities, publications and services.
 


Reader Comments:

Comment by: matshidiso (south Africa ) Tue., Aug. 27, 2013 at 9:52 am EDT
i have lost my body sheap due to the ARV and i'm not confertable anymore with my self do you think i'll ever gain the fat on my legs ever again and be able to were things that i'll be confeterble in?
Reply to this comment


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement